Bobby Liaw, MD, explains the potential treatment strategy for a prostate cancer case with low-volume metastatic disease.
Videos
A prostate cancer expert reviews the treatment approach in the presented case of biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease.
Dr. Bobby Liaw compares the available first-line therapy options for metastatic castration-sensitive prostate cancer and explains how to decide on a therapy.
An oncologist details the first-line therapy options for metastatic castration-sensitive prostate cancer.
Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.
Chukwuemeka Ihemelandu, MD, explains the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.
Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.
Annelise Wilhite, MD, a gynecology oncology fellow at the University of South Alabama Health, discusses the difficulty in treating vulvar and vaginal melanomas.
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.
Ruben Niesvizky, MD, discusses the shift in standard of care treatment for multiple myeloma.
John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.
An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.
John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.
A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.
Two oncologists explain how patients can better understand the NCCN Clinical Practice Guidelines.
Two oncologists discuss the NCCN Clinical Practice Guidelines for triple-negative breast cancer.
John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.
A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.
David M. O’Malley, MD, discusses the management of adverse events across various regimens for cervical cancer treatment and provides insight on future directions for disease management.
Dr David M. O’Malley comments on emerging agents in the pipeline for the treatment of recurrent/metastatic cervical cancer and shares his approach to the sequencing of therapies.
David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.
Dr David M. O’Malley reviews ESMO 2021 updates evaluating the use of combination anti-PD-1 and anti-CTLA4 agents for recurrent and metastatic cervical cancer.
An expert gynecologic oncologist discusses the rationale for using PD-L1 inhibitors and CTLA4 inhibitors in gynecologic cancers.
David M. O’Malley, MD, provides insight on the evolution of cervical cancer and reviews current systemic treatment options for recurrent and advanced disease.
The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
Suggestions to hematologist-oncologists when talking to patients with relapsed/refractory diffuse large B-cell lymphoma about the potential benefits of CAR T-cell therapy and toxicities.
John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.
Rajneesh Nath, MD, discusses the design of the SIERRA trial (NCT02665065), which evaluated 131 I apamistamab (Iomab-B) in elderly patients with relapsed/refractory acute myeloid leukemia.
Ron Bose, MD, PhD, discusses the importance of computer simulations to develop treatments for patients with HER2-positive breast cancer as established by a recent study.
Karen Reckamp, MD, and Jyoti Patel, MD, discuss unmet needs, novel treatment strategies, and future perspectives for patients with ALK+ advanced NSCLC.